Cytokinetics INC Form 4 insider transactions

Cytokinetics' VP, Chief Accounting Officer Robert Wong, reports the acquisition of restricted stock units and stock options.

EVP and Chief Commercial Officer of Cytokinetics, Andrew Callos, reports the acquisition of restricted stock units and stock options.

EVP of Research & Development at Cytokinetics, Fady Ibraham Malik, reports the acquisition of restricted stock units and stock options.

Robert Blum, President & CEO of Cytokinetics, reports acquisition of restricted stock units and stock options.

Robert Wong, VP, Chief Accounting Officer of Cytokinetics Inc., reports disposals of common stock to cover withholding obligations related to vesting Restricted Stock Units.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reports the withholding of shares to cover tax obligations related to vesting Restricted Stock Units.

Cytokinetics' CEO, Robert Blum, reports the withholding of company shares to cover tax obligations related to vesting Restricted Stock Units.

EVP and Chief Commercial Officer of Cytokinetics, Andrew Callos, reports disposals of common stock to cover withholding tax obligations related to vesting Restricted Stock Units.

EVP of Research & Development at Cytokinetics, Fady Ibraham Malik, reports the sale and acquisition of company stock and stock options on March 5, 2024, under a pre-arranged 10b5-1 trading plan.